Literature DB >> 32477569

Hepatitis D infection: from initial discovery to current investigational therapies.

Ben L Da1, Theo Heller2, Christopher Koh2.   

Abstract

Hepatitis D is the most severe form of viral hepatitis associated with a more rapid progression to cirrhosis and an increased risk of hepatocellular carcinoma and mortality compared with hepatitis B mono-infection. Although once thought of as a disappearing disease, hepatitis D is now becoming recognized as a serious worldwide issue due to improvement in diagnostic testing and immigration from endemic countries. Despite these concerns, there is currently only one accepted medical therapy (pegylated-interferon-α) for the treatment of hepatitis D with less than desirable efficacy and significant side effects. Due to these reasons, many patients never undergo treatment. However, increasing knowledge about the virus and its life cycle has led to the clinical development of multiple promising new therapies that hope to alter the natural history of this disease and improve patient outcome. In this article, we will review the literature from discovery to the current investigational therapies. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University.

Entities:  

Keywords:  Hepatitis D; epidemiology; hepatitis B; natural history; novel therapies; outcome; treatment

Year:  2019        PMID: 32477569      PMCID: PMC6691517          DOI: 10.1093/gastro/goz023

Source DB:  PubMed          Journal:  Gastroenterol Rep (Oxf)


  174 in total

1.  Chronic HDV/HBV co-infection: predictors of disease stage---a case series of HDV-3 patients.

Authors:  Wornei Silva Miranda Braga; Cintia Mara Costa de Oliveira; José Ribamar de Araújo; Marcia da Costa Castilho; Joelma Martins Rocha; Joao Bosco de Lima Gimaque; Maria Luana Cristiny Rodrigues Silva; Heline Lira Vasconcelos; Rajendranath Ramasawmy; Raymundo Paraná
Journal:  J Hepatol       Date:  2014-06-04       Impact factor: 25.083

2.  Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease.

Authors:  Cihan Yurdaydin; Onur Keskin; Çagdas Kalkan; Fatih Karakaya; Aysun Çaliskan; Gökhan Kabaçam; F Oguz Önder; Senem Karatayli; Ersin Karatayli; Xheni Deda; Hakan Bozkaya; A Mithat Bozdayi; Ramazan Idilman
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 5.226

Review 3.  Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.

Authors:  Christian Bréchot
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 4.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

5.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

6.  Epidemiology and clinical outcomes of hepatitis delta (D) virus infection in Queensland, Australia.

Authors:  Sarah Coghill; John McNamara; Marion Woods; Krispin Hajkowicz
Journal:  Int J Infect Dis       Date:  2018-07-09       Impact factor: 3.623

7.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

8.  Design of potential siRNA molecules for hepatitis delta virus gene silencing.

Authors:  Sarita Singh; Sunil Kumar Gupta; Anuradha Nischal; Sanjay Khattri; Rajendra Nath; Kamlesh Kumar Pant; Prahlad Kishore Seth
Journal:  Bioinformation       Date:  2012-08-24

9.  Anti-HDV IgM as a marker of disease activity in hepatitis delta.

Authors:  Anika Wranke; Benjamin Heidrich; Stefanie Ernst; Beatriz Calle Serrano; Florin Alexandru Caruntu; Manuela Gabriela Curescu; Kendal Yalcin; Selim Gürel; Stefan Zeuzem; Andreas Erhardt; Stefan Lüth; George V Papatheodoridis; Birgit Bremer; Judith Stift; Jan Grabowski; Janina Kirschner; Kerstin Port; Markus Cornberg; Christine S Falk; Hans-Peter Dienes; Svenja Hardtke; Michael P Manns; Cihan Yurdaydin; Heiner Wedemeyer
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

10.  Prevalence of hepatitis delta antibody among HBsAG carriers in Saudi Arabia.

Authors:  Ibrahim Al-Traif; Amjad Ali; Mutasim Dafalla; Waleed Al-Tamimi; Leila Qassem
Journal:  Ann Saudi Med       Date:  2004 Sep-Oct       Impact factor: 1.526

View more
  2 in total

1.  A Mathematical Model for early HBV and -HDV Kinetics during Anti-HDV Treatment.

Authors:  Rami Zakh; Alexander Churkin; William Bietsch; Menachem Lachiany; Scott J Cotler; Alexander Ploss; Harel Dahari; Danny Barash
Journal:  Mathematics (Basel)       Date:  2021-12-20

Review 2.  Hepatitis D Review: Challenges for the Resource-Poor Setting.

Authors:  Alice U Lee; Caroline Lee
Journal:  Viruses       Date:  2021-09-23       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.